Evidence map›Paper›PMID 37509663›Full record

ArticleBiomedicines2023

Exploratory Longitudinal Study of Ocular Structural and Visual Functional Changes in Subjects at High Genetic Risk of Developing Alzheimer's Disease.

Inés López-Cuenca, Lidia Sánchez-Puebla, Elena Salobrar-García, María Álvarez-Gutierrez, Lorena Elvira-Hurtado, Ana Barabash, Federico Ramírez-Toraño, José A Fernández-Albarral, José A Matamoros, Alberto Nebreda and 7 more

Abstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Ocular changes as potential biomarkers for early diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Inés López-CuencaRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0003-0511-515X
Lidia Sánchez-PueblaRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.
Elena Salobrar-GarcíaRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0001-5939-5551
María Álvarez-GutierrezRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.
Lorena Elvira-HurtadoRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.
Ana BarabashHealth Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.ORCID 0000-0003-2383-1563
Federico Ramírez-TorañoCenter for Cognitive and Computational Neuroscience Laboratory of Cognitive and Computational Neurscience, Complutense University of Madrid, 28223 Pozuelo de Alarcón, Spain.
José A Fernández-AlbarralRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0003-0399-7996
José A MatamorosRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.
Alberto NebredaCenter for Cognitive and Computational Neuroscience Laboratory of Cognitive and Computational Neurscience, Complutense University of Madrid, 28223 Pozuelo de Alarcón, Spain.
Alejandra García-ColomoCenter for Cognitive and Computational Neuroscience Laboratory of Cognitive and Computational Neurscience, Complutense University of Madrid, 28223 Pozuelo de Alarcón, Spain.ORCID 0000-0003-1817-6007
Ana I RamírezRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-2656-4723
Juan J SalazarRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0001-5480-5902
Pedro GilHealth Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Fernando MaestúHealth Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
José M RamírezRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-5145-5094
Rosa de HozRamon Castroviejo Institute for Ophthalmic Research, Complutense University of Madrid, 28040 Madrid, Spain.ORCID 0000-0002-1581-087X

Funding

Complutense University of Madrid CT58/21-CT59/21Complutense University of Madrid CT82/20-CT83/20NEUROCENTRO B2017/BMD-3760Spanish Ministry of Economy FPU18/05768Spanish Ministry of Economy PRE2019-087612Spanish Ministry of Economy and Competitiveness PSI2015-68793-C3-1-R [D601]Spanish Ministry of Science and Innovation (RD16/0008/0005)Spanish Ministry of Science and Innovation. Complimentary,Research Network RETIBRAIN RED2018-102499-T
6 · The paper itself

Abstract

This study aimed to analyze the evolution of visual changes in cognitively healthy individuals at risk for Alzheimer's disease (AD). Participants with a first-degree family history of AD (FH+) and carrying the Ε4+ allele for the ApoE gene (ApoE ε4+) underwent retinal thickness analysis using optical coherence tomography (OCT) and visual function assessments, including visual acuity (VA), contrast sensitivity (CS), color perception, perception digital tests, and visual field analysis. Structural analysis divided participants into FH+ ApoE ε4+ and FH- ApoE ε4- groups, while functional analysis further categorized them by age (40-60 years and over 60 years). Over the 27-month follow-up, the FH+ ApoE ε4+ group exhibited thickness changes in all inner retinal layers. Comparing this group to the FH- ApoE ε4- group at 27 months revealed progressing changes in the inner nuclear layer. In the FH+ ApoE ε4+ 40-60 years group, no progression of visual function changes was observed, but an increase in VA and CS was maintained at 3 and 12 cycles per degree, respectively, compared to the group without AD risk at 27 months. In conclusion, cognitively healthy individuals at risk for AD demonstrated progressive retinal structural changes over the 27-month follow-up, while functional changes remained stable.

Indexed as

Alzheimer’s diseaseApoE ε4contrast sensitivityfamiliar historygenetic riskoptical coherence tomographyvisual acuity

Identifiers

PMID37509663
PMCPMC10377092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.